One-Shot cell therapy aims to reset immune system in severe lupus
NCT ID NCT06984341
Summary
This early-stage study is testing a new cell therapy called P-CD19CD20-ALLO1 in adults with severe, treatment-resistant lupus. The main goal is to see if the treatment is safe and how the body handles it. Researchers will also look for signs that it can control lupus activity and potentially allow patients to stop taking other immunosuppressant drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham: The Kirklin Clinic
RECRUITINGBirmingham, Alabama, 35233, United States
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.